Vincent T. Ho, MD

Vincent T. Ho, MD

Medical Oncology

Contact Information

Office Phone Number

617-632-6256

Fax

617-632-4422

Appointments

617-632-5138

Biography

Vincent T. Ho, MD

Dr. Ho received his MD from Harvard Medical School in 1996. He completed postgraduate training at Brigham & Women's Hospital, followed by a fellowship at DFCI. He joined DFCI in 2002, where he is a member of the Hematologic Malignancies staff.

Researcher

Physician

Director of Clinical Operations, Stem Cell Transplantation
Institute Physician
Professor of Medicine, Harvard Medical School

Centers/Programs

Stem Cell Transplantation

Clinical Interests

Germ cell tumor, Leukemias, Lymphoma, Myelodysplasia, Stem cell/bone marrow transplant

Board Certification

  • Internal Medicine, 1999
  • Medical Oncology, 2002

Fellowship

  • Dana-Farber/Partners CancerCare, Medical Oncology

Residency

  • Brigham and Women's Hospital, Internal Medicine

Medical School

  • Harvard Medical School

Publications

    • Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival. Blood Adv. 2024 May 15. View in: Pubmed

    • Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Transplant Cell Ther. 2024 Jul; 30(7):687.e1-687.e13. View in: Pubmed

    • Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect. Front Immunol. 2024; 15:1359113. View in: Pubmed

    • Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 Feb 27; 8(4):978-990. View in: Pubmed

    • Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions. Blood Adv. 2024 02 13; 8(3):667-680. View in: Pubmed

    • Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplant Cell Ther. 2024 Feb; 30(2):233.e1-233.e14. View in: Pubmed

    • Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023 08 08; 7(15):4080-4088. View in: Pubmed

    • Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023 08 08; 7(15):3903-3915. View in: Pubmed

    • Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): a study protocol for a multicentre, colonoscopist-blinded, randomised controlled trial. BMJ Open. 2023 07 21; 13(7):e073843. View in: Pubmed

    • Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. Br J Dermatol. 2023 07 07; 189(1):132-134. View in: Pubmed

    • Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability. Transplant Cell Ther. 2023 09; 29(9):539-547. View in: Pubmed

    • Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 06 15; 141(24):2932-2943. View in: Pubmed

    • Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells. Blood Adv. 2023 06 13; 7(11):2431-2435. View in: Pubmed

    • Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2023 06 13; 7(11):2309-2316. View in: Pubmed

    • Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight. 2023 06 08; 8(11). View in: Pubmed

    • Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. Clin Cancer Res. 2023 06 01; 29(11):2034-2042. View in: Pubmed

    • Transcriptome and Proteome Profiling of Primary Human Gastric Interstitial Cells of Cajal Predicts Pacemaker Networks. J Neurogastroenterol Motil. 2023 Apr 30; 29(2):238-249. View in: Pubmed

    • Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. View in: Pubmed

    • Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 07; 29(7):455.e1-455.e9. View in: Pubmed

    • NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 02; 21(2):108-115. View in: Pubmed

    • Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. Leuk Res. 2023 02; 125:107004. View in: Pubmed

    • Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study. Transplant Cell Ther. 2023 03; 29(3):166.e1-166.e10. View in: Pubmed

    • Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023 03; 29(3):151-163. View in: Pubmed

    • Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022 11 22; 6(22):5857-5865. View in: Pubmed

    • A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022 11 08; 6(21):5786-5796. View in: Pubmed

    • Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica. 2022 11 01; 107(11):2617-2629. View in: Pubmed

    • Placental abnormalities in type 1 and type 2 diabetes mellitus: a systematic review and metaanalysis of shear wave elastography. Am J Obstet Gynecol MFM. 2022 Nov; 4(6):100736. View in: Pubmed

    • Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity. Clin Infect Dis. 2022 08 24; 75(1):e920-e923. View in: Pubmed

    • Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022 08 09; 6(15):4392-4402. View in: Pubmed

    • Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022 06 16; 139(24):3546-3557. View in: Pubmed

    • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Sci Transl Med. 2022 06 15; 14(649):eaba4380. View in: Pubmed

    • Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. Br J Haematol. 2022 08; 198(4):785-789. View in: Pubmed

    • Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11). View in: Pubmed

    • Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. Transplant Cell Ther. 2022 08; 28(8):508.e1-508.e8. View in: Pubmed

    • GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194. View in: Pubmed

    • Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation. Transplant Cell Ther. 2022 07; 28(7):402.e1-402.e5. View in: Pubmed

    • The CCEDRRN COVID-19 Mortality Score to predict death among nonpalliative patients with COVID-19 presenting to emergency departments: a derivation and validation study. CMAJ Open. 2022 Jan-Mar; 10(1):E90-E99. View in: Pubmed

    • Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Adv. 2022 01 11; 6(1):181-188. View in: Pubmed

    • Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545. View in: Pubmed

    • Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol. 2021 Dec 19; 10(1):57. View in: Pubmed

    • Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021 12 14; 5(23):5140-5149. View in: Pubmed

    • Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368. View in: Pubmed

    • Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222. View in: Pubmed

    • Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. Open Forum Infect Dis. 2021 Dec; 8(12):ofab504. View in: Pubmed

    • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2022 01 10; 40(2):189-201. View in: Pubmed

    • Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021 12; 27(12):990.e1-990.e7. View in: Pubmed

    • Microfluidic integrated capacitive biosensor for C-reactive protein label-free and real-time detection. Analyst. 2021 Sep 07; 146(17):5380-5388. View in: Pubmed

    • Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 09; 27(9):759.e1-759.e8. View in: Pubmed

    • Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217. View in: Pubmed

    • Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217. View in: Pubmed

    • Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223. View in: Pubmed

    • Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv. 2021 03 23; 5(6):1585-1593. View in: Pubmed

    • Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659. View in: Pubmed

    • Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683. View in: Pubmed

    • Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7. View in: Pubmed

    • Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2021 05; 27(5):433.e1-433.e8. View in: Pubmed

    • COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871. View in: Pubmed

    • Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. J Clin Oncol. 2021 06 10; 39(17):1878-1887. View in: Pubmed

    • Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364. View in: Pubmed

    • Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Adv. 2021 01 12; 5(1):54-60. View in: Pubmed

    • Splenectomy before allogeneic hematopoietic stem-cell transplantation for myelofibrosis: Tumor burden matters! Am J Hematol. 2021 01; 96(1):12-13. View in: Pubmed

    • Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175. View in: Pubmed

    • Parroting Lymphoma. N Engl J Med. 2020 10 01; 383(14):1376-1381. View in: Pubmed

    • Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561). View in: Pubmed

    • Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012. View in: Pubmed

    • Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123. View in: Pubmed

    • Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020 09 01; 130(9):4624-4636. View in: Pubmed

    • Class 3 Obesity in a Multidisciplinary Metabolic Weight Management Program: The Effect of Preexisting Type 2 Diabetes on 6-Month Weight Loss. J Diabetes Res. 2020; 2020:9327910. View in: Pubmed

    • A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191. View in: Pubmed

    • BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893. View in: Pubmed

    • Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2020 05 01; 18(5):599-634. View in: Pubmed

    • Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy. Sci Transl Med. 2020 03 25; 12(536). View in: Pubmed

    • Aberrant Expression of RAD52, Its Prognostic Impact in Rectal Cancer and Association with Poor Survival of Patients. Int J Mol Sci. 2020 Mar 04; 21(5). View in: Pubmed

    • Prevalence and effects of gastro-oesophageal reflux during spirometry in subjects undergoing reflux assessment. PLoS One. 2020; 15(2):e0229250. View in: Pubmed

    • Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2020 05; 26(5):884-892. View in: Pubmed

    • Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. Blood. 2019 Nov 13; 134(Supplement_1):48. View in: Pubmed

    • Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539. View in: Pubmed

    • A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810. View in: Pubmed

    • Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561. View in: Pubmed

    • Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Hematol Int. 2019 Dec; 1(4):201-204. View in: Pubmed

    • Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. Clin Infect Dis. 2019 08 16; 69(5):869-872. View in: Pubmed

    • Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019 12; 25(12):2383-2387. View in: Pubmed

    • Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204. View in: Pubmed

    • Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis. Biol Blood Marrow Transplant. 2019 08; 25(8):1642-1647. View in: Pubmed

    • Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994. View in: Pubmed

    • Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979. View in: Pubmed

    • Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. J Rheumatol. 2019 07; 46(7):751-754. View in: Pubmed

    • Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2019 Jan 21; 20(1):15. View in: Pubmed

    • A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica. 2019 07; 104(7):e314-e317. View in: Pubmed

    • Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. J Invest Dermatol. 2019 03; 139(3):591-599. View in: Pubmed

    • Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer. 2019 Feb; 17(1):58-64.e1. View in: Pubmed

    • Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis. BMC Cancer. 2018 Sep 03; 18(1):869. View in: Pubmed

    • Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Adv. 2018 08 14; 2(15):1882-1888. View in: Pubmed

    • Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144. View in: Pubmed

    • Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant. 2018 11; 24(11):2216-2223. View in: Pubmed

    • Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. Biol Blood Marrow Transplant. 2018 10; 24(10):2164-2165. View in: Pubmed

    • Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2018 10; 24(10):2072-2080. View in: Pubmed

    • Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827. View in: Pubmed

    • Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353. View in: Pubmed

    • Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol. 2018 Sep; 27(3):402-408. View in: Pubmed

    • A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740. View in: Pubmed

    • Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845. View in: Pubmed

    • a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379. View in: Pubmed

    • Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530. View in: Pubmed

    • Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Rev Clin Pharmacol. 2018 Feb; 11(2):113-124. View in: Pubmed

    • Early Postoperative Low Expression of RAD50 in Rectal Cancer Patients Associates with Disease-Free Survival. Cancers (Basel). 2017 Nov 30; 9(12). View in: Pubmed

    • Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520. View in: Pubmed

    • Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279. View in: Pubmed

    • Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899. View in: Pubmed

    • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35(36):4003-4011. View in: Pubmed

    • Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017 Nov; 77(5):845-854.e5. View in: Pubmed

    • An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood. 2017 11 09; 130(19):2131-2145. View in: Pubmed

    • Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2017 Nov; 6(3):75-93. View in: Pubmed

    • Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation. Clin Infect Dis. 2017 Aug 01; 65(3):510-513. View in: Pubmed

    • Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 08 31; 130(9):1156-1164. View in: Pubmed

    • Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1767-1772. View in: Pubmed

    • Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep; 124(3):253-260. View in: Pubmed

    • Incidence of clinically relevant medication errors in the era of electronically prepopulated medication reconciliation forms: a retrospective chart review. CMAJ Open. 2017 May 05; 5(2):E345-E353. View in: Pubmed

    • Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94. View in: Pubmed

    • Quantitative computed tomography assessment of bronchiolitis obliterans syndrome after lung transplantation. Clin Transplant. 2017 05; 31(5). View in: Pubmed

    • Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 07; 102(7):1185-1191. View in: Pubmed

    • PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197. View in: Pubmed

    • Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. 2017 06 01; 123(11):2025-2034. View in: Pubmed

    • Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388. View in: Pubmed

    • Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605. View in: Pubmed

    • Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284. View in: Pubmed

    • Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278. View in: Pubmed

    • Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. Ann Am Thorac Soc. 2016 11; 13(11):1932-1939. View in: Pubmed

    • Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850. View in: Pubmed

    • Real Incidence of Vestibular Schwannoma? Estimations From a National Registry. Otol Neurotol. 2016 10; 37(9):1411-7. View in: Pubmed

    • An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091. View in: Pubmed

    • Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 10 06; 128(14):1845-1853. View in: Pubmed

    • Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504. View in: Pubmed

    • Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. View in: Pubmed

    • A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259. View in: Pubmed

    • Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9. View in: Pubmed

    • Sonographic Appearance of the Gallbladder in the Allogeneic Hematopoietic Stem Cell Transplant Population. J Ultrasound Med. 2016 Jul; 35(7):1403-9. View in: Pubmed

    • Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7. View in: Pubmed

    • The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1977-9. View in: Pubmed

    • Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97. View in: Pubmed

    • Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505. View in: Pubmed

    • The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr; 173(1):96-104. View in: Pubmed

    • Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8. View in: Pubmed

    • Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57. View in: Pubmed

    • Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. Am J Hematol. 2016 Jan; 91(1):123-30. View in: Pubmed

    • Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol. 2016 Mar 10; 34(8):810-5. View in: Pubmed

    • Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Apr; 22(4):710-716. View in: Pubmed

    • INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2015 Oct; 35(10):1992-2000. View in: Pubmed

    • Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):80-5. View in: Pubmed

    • Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7. View in: Pubmed

    • A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13. View in: Pubmed

    • Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8. View in: Pubmed

    • Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1479-87. View in: Pubmed

    • Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015 Aug; 29(8):1754-62. View in: Pubmed

    • Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1046-1053. View in: Pubmed

    • Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80. View in: Pubmed

    • A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr; 21(4):761-7. View in: Pubmed

    • A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015 Jan; 2(1):e21-9. View in: Pubmed

    • Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8. View in: Pubmed

    • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb; 21(2):266-74. View in: Pubmed

    • Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8. View in: Pubmed

    • Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20; 124(22):3221-7; quiz 3335. View in: Pubmed

    • Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6. View in: Pubmed

    • Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8. View in: Pubmed

    • A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43. View in: Pubmed

    • Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1717-21. View in: Pubmed

    • Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21. View in: Pubmed

    • Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1418-25. View in: Pubmed

    • Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508. View in: Pubmed

    • Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 2014 May 29; 123(22):3504-11. View in: Pubmed

    • Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 Jun; 20(6):858-64. View in: Pubmed

    • White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7. View in: Pubmed

    • Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies. Skin Therapy Lett. 2014 Mar-Apr; 19(2):1-4. View in: Pubmed

    • Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9. View in: Pubmed

    • Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75. View in: Pubmed

    • BK virus disease after allogeneic stem cell transplantation: a cohort analysis. Biol Blood Marrow Transplant. 2014 Apr; 20(4):564-70. View in: Pubmed

    • Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013 Dec 05; 122(24):3871-8. View in: Pubmed

    • Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1713-8. View in: Pubmed

    • Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol. 2013 Sep; 37(9):1319-28. View in: Pubmed

    • Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81. View in: Pubmed

    • ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39. View in: Pubmed

    • Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65. View in: Pubmed

    • Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol. 2013 Aug; 169(2):320-8. View in: Pubmed

    • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7. View in: Pubmed

    • Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80. View in: Pubmed

    • Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43. View in: Pubmed

    • Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7. View in: Pubmed

    • Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702. View in: Pubmed

    • One-year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis in a Canadian population. J Cutan Med Surg. 2013 Mar-Apr; 17(2):129-38. View in: Pubmed

    • Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11. View in: Pubmed

    • Prognostic significance of Fbw7 in human melanoma and its role in cell migration. J Invest Dermatol. 2013 Jul; 133(7):1794-802. View in: Pubmed

    • KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2. View in: Pubmed

    • Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. Biol Blood Marrow Transplant. 2013 Mar; 19(3):481-5. View in: Pubmed

    • Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. 2013 Jun; 48(6):825-31. View in: Pubmed

    • Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013 Jan; 12(1):123-36. View in: Pubmed

    • Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83. View in: Pubmed

    • Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice. J Cutan Med Surg. 2012 Nov-Dec; 16(6):407-16. View in: Pubmed

    • The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012 Nov; 167(5):1145-52. View in: Pubmed

    • Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90. View in: Pubmed

    • Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012 Nov; 44(11):1236-42. View in: Pubmed

    • Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):593-7. View in: Pubmed

    • Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012 Sep 01; 10(5):343-53. View in: Pubmed

    • Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9. View in: Pubmed

    • Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8. View in: Pubmed

    • Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012 Aug; 3(4):253-65. View in: Pubmed

    • Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8. View in: Pubmed

    • A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13. View in: Pubmed

    • Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7. View in: Pubmed

    • Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1638-48. View in: Pubmed

    • Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72. View in: Pubmed

    • Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012 Apr 19; 119(16):3854-60. View in: Pubmed

    • Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Mol Cell Proteomics. 2012 Jun; 11(6):M111.015479. View in: Pubmed

    • Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66. View in: Pubmed

    • Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12. View in: Pubmed

    • Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51. View in: Pubmed

    • Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7. View in: Pubmed

    • Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study. Int J Dermatol. 2012 Jan; 51(1):104-10. View in: Pubmed

    • The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):708-15. View in: Pubmed

    • Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30. View in: Pubmed

    • Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011 Sep 01; 365(9):815-24. View in: Pubmed

    • Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74. View in: Pubmed

    • Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83. View in: Pubmed

    • Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantation. Clin Genitourin Cancer. 2011 Dec; 9(2):124-9. View in: Pubmed

    • Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011 Jun 23; 117(25):6963-70. View in: Pubmed

    • Ex vivo T cell depletion of allogeneic PBSC as acute and chronic GVHD prophylaxis after myeloablative HCT: time to reconsider? Biol Blood Marrow Transplant. 2011 Aug; 17(8):1112-3. View in: Pubmed

    • Endogenous methicillin-resistant Staphylococcus aureus endophthalmitis. Retina. 2011 Mar; 31(3):596-601. View in: Pubmed

    • (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9. View in: Pubmed

    • A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-1613. View in: Pubmed

    • Invasive fungal disease after remote inoculation in transplant recipients. Clin Infect Dis. 2011 Jan 01; 52(1):e7-10. View in: Pubmed

    • Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204. View in: Pubmed

    • Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71. View in: Pubmed

    • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83. View in: Pubmed

    • Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011 May; 17(5):737-44. View in: Pubmed

    • Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Mar; 17(3):434-8. View in: Pubmed

    • Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8. View in: Pubmed

    • Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60. View in: Pubmed

    • Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67. View in: Pubmed

    • Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010 Dec; 16(12):1693-9. View in: Pubmed

    • CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):e409-11. View in: Pubmed

    • Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatolog Treat. 2010 May; 21(3):157-66. View in: Pubmed

    • Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1442-50. View in: Pubmed

    • Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93. View in: Pubmed

    • Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2010 Mar; 16(3):421-9. View in: Pubmed

    • Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5. View in: Pubmed

    • Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31. View in: Pubmed

    • Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1099-106. View in: Pubmed

    • Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7. View in: Pubmed

    • Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9. View in: Pubmed

    • Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14; 362(2):118-28. View in: Pubmed

    • Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800. View in: Pubmed

    • Esophageal cancer in Indigenous Australians in Far North Queensland. J Gastroenterol Hepatol. 2009 Oct; 24(10):1683-6. View in: Pubmed

    • Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1628-33. View in: Pubmed

    • Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9. View in: Pubmed

    • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30. View in: Pubmed

    • The effect of smoking on allogeneic transplant outcomes. Biol Blood Marrow Transplant. 2009 Oct; 15(10):1277-87. View in: Pubmed

    • Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol. 2009 Aug; 2(4):365-76. View in: Pubmed

    • Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009 Jul-Aug; 13(4):192-7. View in: Pubmed

    • Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50. View in: Pubmed

    • Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1049-59. View in: Pubmed

    • Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16; 114(3):511-7. View in: Pubmed

    • The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009 Apr; 48(4):348-55. View in: Pubmed

    • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74. View in: Pubmed

    • High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002. View in: Pubmed

    • Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8. View in: Pubmed

    • Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74. View in: Pubmed

    • Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31. View in: Pubmed

    • Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug; 14(8):920-6. View in: Pubmed

    • The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008 Oct 15; 112(8):3073-81. View in: Pubmed

    • Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol. 2008 Jun; 21(2):223-37. View in: Pubmed

    • Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Rep. 2008 May 01; 2:140. View in: Pubmed

    • Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25. View in: Pubmed

    • Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb; 14(2):197-207. View in: Pubmed

    • The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):23-32. View in: Pubmed

    • Misoprostol associated refractile material in fetal and placental tissues after medical termination of pregnancy. Am J Surg Pathol. 2007 Dec; 31(12):1893-6. View in: Pubmed

    • Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9. View in: Pubmed

    • A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35. View in: Pubmed

    • Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008 Feb; 41(3):229-37. View in: Pubmed

    • Quantitative measurement of postural sway in mouse models of human neurodegenerative disease. Neuroscience. 2007 Sep 21; 148(4):825-32. View in: Pubmed

    • Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 Aug; 40(3):209-17. View in: Pubmed

    • Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost. 2007 Jun; 33(4):373-88. View in: Pubmed

    • Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. J Dermatol. 2007 Apr; 34(4):231-6. View in: Pubmed

    • Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 01; 109(7):3108-14. View in: Pubmed

    • Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007 Jul 15; 110(2):490-500. View in: Pubmed

    • Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64. View in: Pubmed

    • Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8. View in: Pubmed

    • Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9. View in: Pubmed

    • Twelve years' local experience in ambulatory anaesthesia. Hong Kong Med J. 2006 Oct; 12(5):339-44. View in: Pubmed

    • Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55. View in: Pubmed

    • Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64. View in: Pubmed

    • Contextual emotion-regulation therapy for childhood depression: description and pilot testing of a new intervention. J Am Acad Child Adolesc Psychiatry. 2006 Aug; 45(8):892-903. View in: Pubmed

    • Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006 Aug; 38(4):305-10. View in: Pubmed

    • Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer. 2006 Jul 03; 95(1):80-6. View in: Pubmed

    • HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May; 37(9):845-50. View in: Pubmed

    • Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62. View in: Pubmed

    • Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg. 2006; 9 Suppl 1:4-9. View in: Pubmed

    • Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg. 2006; 9 Suppl 1:18-25. View in: Pubmed

    • Hypertension in cancer patients seeking acute care: an opportunity to intervene. Am J Med Sci. 2005 Sep; 330(3):120-7. View in: Pubmed

    • Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Aug; 11(8):571-5. View in: Pubmed

    • Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Jul; 11(7):551-7. View in: Pubmed

    • Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May; 11(5):383-8. View in: Pubmed

    • Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005 May; 124(5):1044-52. View in: Pubmed

    • Predictors of breast and cervical screening in Vietnamese women in Harris County, Houston, Texas. Cancer Nurs. 2005 Mar-Apr; 28(2):119-29; quiz 130-1. View in: Pubmed

    • Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg. 2005; 8 Suppl 5:1-9. View in: Pubmed

    • Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83. View in: Pubmed

    • Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8. View in: Pubmed

    • Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004 Dec; 34(11):987-94. View in: Pubmed

    • Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004 Oct; 10(10):655-68. View in: Pubmed

    • Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4. View in: Pubmed

    • Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg. 2004 Sep-Oct; 8(5):321-37. View in: Pubmed

    • Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer. 2004 Sep; 12(9):657-62. View in: Pubmed

    • Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Rev Clin Exp Hematol. 2004 Jun 01; 8(1):E3. View in: Pubmed

    • Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004 Sep 01; 104(5):1559-64. View in: Pubmed

    • Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10(5):328-36. View in: Pubmed

    • Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6. View in: Pubmed

    • Effect of delay in initiating radiotherapy for patients with early stage breast cancer. Clin Oncol (R Coll Radiol). 2004 Feb; 16(1):6-11. View in: Pubmed

    • Donor lymphocyte infusions. Adv Pharmacol. 2004; 51:319-45. View in: Pubmed

    • Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003 Nov; 10(6):451-62. View in: Pubmed

    • Aberrant expression of T-plastin in Sezary cells. Cancer Res. 2003 Nov 01; 63(21):7122-7. View in: Pubmed

    • The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003 Oct; 32(8):771-5. View in: Pubmed

    • Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82. View in: Pubmed

    • Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch Dermatol. 2003 May; 139(5):624-8. View in: Pubmed

    • Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5. View in: Pubmed

    • Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg. 2003 May-Jun; 7(3):193-7. View in: Pubmed

    • Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002 Oct 15; 100(8):2697-702. View in: Pubmed

    • Assessment of the factors associated with flavivirus seroprevalence in a population in Southern Vietnam. Epidemiol Infect. 2002 Apr; 128(2):213-20. View in: Pubmed

    • Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002 Mar; 109(3):539-46. View in: Pubmed

    • The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001 Dec 01; 98(12):3192-204. View in: Pubmed

    • A fatigue clinic in a comprehensive cancer center: design and experiences. Cancer. 2001 Sep 15; 92(6 Suppl):1708-13. View in: Pubmed

    • Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001 Feb 01; 91(3):585-91. View in: Pubmed

    • Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):223-9. View in: Pubmed

    • Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMAJ. 2000 Jul 11; 163(1):31-6. View in: Pubmed

    • Evolution of the volume-outcome relation for hospitals performing coronary angioplasty. Circulation. 2000 Apr 18; 101(15):1806-11. View in: Pubmed

    • Multiple approaches to assessing the effects of delays for hip fracture patients in the United States and Canada. Health Serv Res. 2000 Mar; 34(7):1499-518. View in: Pubmed

    • A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging. 1999 Feb; 9(2):240-50. View in: Pubmed

    • Does practice make perfect? Examining the relationship between hospital surgical volume and outcomes for hip fracture patients in Quebec. Med Care. 1998 Jun; 36(6):892-903. View in: Pubmed

    • Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res. 1998 Feb; 8(1):17-23. View in: Pubmed

    • The cloning, expression and characterization of a cellobiase gene encoding a secretory enzyme from Cellulomonas biazotea. Gene. 1998 Jan 19; 207(1):79-86. View in: Pubmed

    • Induction of squamous cell carcinoma in p53-deficient mice after ultraviolet irradiation. J Invest Dermatol. 1998 Jan; 110(1):72-5. View in: Pubmed

    • Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Kidney Int. 1997 Feb; 51(2):548-52. View in: Pubmed

    • Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1997 Jan; 36(1):114-7. View in: Pubmed

    • Effects of transition metals on the expression of the erythropoietin gene: further evidence that the oxygen sensor is a heme protein. Biochem Biophys Res Commun. 1996 Jun 05; 223(1):175-80. View in: Pubmed

    • Somatic mosaicism in a patient with neurofibromatosis type 1. Am J Hum Genet. 1996 Mar; 58(3):484-90. View in: Pubmed

    • Low-grade adenocarcinoma of probable endolymphatic sac origin: CT and MR appearance. AJNR Am J Neuroradiol. 1996 Jan; 17(1):168-70. View in: Pubmed

    • Treatment of severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Invest Dermatol. 1995 May; 104(5 Suppl):36S. View in: Pubmed

    • Use of a marked erythropoietin gene for investigation of its cis-acting elements. J Biol Chem. 1995 Apr 28; 270(17):10084-90. View in: Pubmed

    • Criterion and predictive validity of the diagnosis of adjustment disorder: a prospective study of youths with new-onset insulin-dependent diabetes mellitus. Am J Psychiatry. 1995 Apr; 152(4):523-8. View in: Pubmed

    • Postsurgical conjunctival epithelial cysts. AJNR Am J Neuroradiol. 1994 Jun; 15(6):1181-3. View in: Pubmed

    • Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1993 Nov; 29(5 Pt 1):729-35. View in: Pubmed

    • Unusual subcutaneous sarcoidosis of the face. AJNR Am J Neuroradiol. 1992 Nov-Dec; 13(6):1619-21. View in: Pubmed

    • Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol. 1990 Sep; 23(3 Pt 1):413-21. View in: Pubmed

    • UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol. 1990 Sep; 95(3):275-82. View in: Pubmed

    • Laryngeal constriction in normal humans during experimentally induced bronchoconstriction. J Appl Physiol (1985). 1985 Feb; 58(2):352-6. View in: Pubmed

    • Role of emergency skull x-ray films in the evaluation of the head-injured patient: a retrospective study. Neurosurgery. 1983 Aug; 13(2):136-40. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Vincent T. Ho, MD

    About Our Ratings

    Physician Star Rating Comment Block

    Discovery and Insights